Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu

TVB- 2640 in Combination With Bevacizumab in Patients With First Relapse of High Grade Astrocytoma

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03032484
Recruitment Status : Recruiting
First Posted : January 26, 2017
Last Update Posted : October 26, 2018
Sponsor:
Information provided by (Responsible Party):
Andrew Brenner, The University of Texas Health Science Center at San Antonio

Brief Summary:
Randomized phase 2 study TVB-2640 in combination with Bevacizumab versus Bevacizumab alone.

Condition or disease Intervention/treatment Phase
Astrocytoma Drug: Bevacizumab Drug: TVB-2640 Phase 2

Detailed Description:

Eligible patients will be randomized into 2 separate arms:

  • Arm number one will receive Bevacizumab every 2 weeks in combination with TVB-2640 from day 1 until day 28 of the first cycle.
  • Arm number two will receive Bevacizumab alone every 2 weeks, from on days 1 and 15 of the first until day 28 of the first cycle.
  • MR-Spectroscopy will be obtained on all patients (both arms) at day 28 of first cycle.
  • Starting on cycle 2 day 1, all patients will converge to a single arm and will continue to receive bevacizumab every 2 weeks in combination with TVB-2640. Every cycle will last 28 days.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 24 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase 2 Investigator Initiated Study to Determine the Efficacy and Safety of TVB- 2640 in Combination With Bevacizumab in Patients With First Relapse of High Grade Astrocytoma
Actual Study Start Date : May 18, 2017
Estimated Primary Completion Date : April 10, 2021
Estimated Study Completion Date : April 10, 2021

Resource links provided by the National Library of Medicine

Drug Information available for: Bevacizumab

Arm Intervention/treatment
Experimental: Bevacizumab and TVB-2640
Bevacizumab every 2 weeks in combination with TVB-2640 dosed at 100mg/m2 daily (rounded to 50mg tab dose), from day 1 until day 28 of the first cycle.
Drug: Bevacizumab
Bevacizumab is FDA approved as a treatment for recurrent Glioblastoma following failure of radiation therapy and temozolomide.
Other Name: Avastin

Drug: TVB-2640
TVB-2640 is a potent and reversible inhibitor of the FASN enzyme. TVB-2640 inhibits the β-ketoacyl reductase (KR) enzymatic activity of the FASN enzyme.

Experimental: Bevacizumab
Bevacizumab alone every 2 weeks, on days 1 and 15 until day 28 of the first cycle.
Drug: Bevacizumab
Bevacizumab is FDA approved as a treatment for recurrent Glioblastoma following failure of radiation therapy and temozolomide.
Other Name: Avastin




Primary Outcome Measures :
  1. Tumor response per RANO (Response Assessment in Neuro-Oncology) criteria [ Time Frame: Measured every 8 weeks for 28 day cycles for the duration of study treatment, estimated to be less than one year ]

Secondary Outcome Measures :
  1. Incidence, nature and severity of adverse events and serious adverse events, graded according to NCI - Common Toxicity Criteria for Adverse Events version (4.03) [ Time Frame: 1.5 years ]

Other Outcome Measures:
  1. Metabolic change analysis of tumor tissue by MRS (Magnetic Resonance Spectroscopy) [ Time Frame: Day 28 of the first cycle ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • At least 18 years of age
  • Ability to understand the purposes and risks of the study and has signed a written informed consent form approved by the investigator's IRB/Ethics Committee
  • Histologically confirmed high-grade astrocytoma
  • Progression following standard combined modality treatment with radiation and temozolomide chemotherapy
  • Recovered from reversible toxicities of prior therapy to Grade 0 or Grade 1
  • ECOG Pperformance Status of 0 to 2
  • Life expectancy of at least 3 months
  • Adequate renal and liver function: AST/ALT ≤ 3 x ULN, Bilirubin ≤ 1.5 times ULN, Creatinine ≤ ULN
  • Adequate hematologic status (without hematologic support): Hemoglobin ≥ 9 g/dL, ANC ≥ 1500 cells/ml, Platelets ≥ 100,000 cells/ml
  • All women of childbearing potential must have a negative serum pregnancy test and male and female subjects must agree to use effective means of contraception (for example, surgical sterilization or the use of barrier contraception with either a condom or diaphragm in conjunction with spermicidal gel or an IUD) with their partner from entry into the study through six months after the last dose.

Exclusion Criteria:

  • Receiving warfarin (or other coumarin derivatives) and is unable to switch to low molecular weight heparin (LMWH) before the first dose of study drug
  • Evidence of acute intracranial or intratumoral hemorrhage either by MRI or CT scan. Subjects with resolving hemorrhage changes punctuate hemorrhage, or hemosiderine are eligible
  • Unable to undergo MRI scan (e.g., pacemaker)
  • Received enzyme-inducing anti-epileptic agents within 14 days of study drug (e.g., carbamazepine, phenytoin, phenobarbital, primidone)
  • Not recovered to a NCI CTCAE v.4.03 Grade ≤ 1 from AEs (except alopecia and lymphopenia) due to surgery, antineoplastic agents, investigational drugs, or other medications that were administered prior to study drug
  • Evidence of wound dehiscence
  • Pregnant or breast-feeding
  • Clinically significant Dry Eye or necessary contact lens use
  • Serious intercurrent illness such as: Hypertension (two or more blood pressure readings performed at screening of > 150 mmHg systolic or > 100 mmHg diastolic) despite optimal treatment, Non-healing wound or ulcer, Uncontrolled life threatening cardiac arrhythmias, Untreated hypothyroidism, Uncontrolled active infection, Symptomatic congestive heart failure or unstable angina pectoris within 3 months prior to study drug, Gastrointestinal perforation, abdominal fistula, intra-abdominal abscess within 1 year
  • Inherited bleeding diathesis or coagulopathy with the risk of bleeding
  • HIV , Hepatitis B or C documented infections
  • Received any of the following prior anticancer therapy: Non-standard radiation therapy such as brachytherapy, systemic radioisotope therapy (RIT), or intra-operative radiotherapy (IORT). Note: stereotactic radiosurgery (SRS) is allowed, Non-antiangiogenic therapy (including investigational agents and small molecular kinase inhibitors) within 7 days or 5 half-lives, whichever is shorter, prior to the first dose of study drug, Biologic agents (antibodies, immune modulators, vaccines, cytokines) within 21 days prior to first dose of study drug, Nitrosoureas or mitomycin C within 42 days or metronomic/protracted

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03032484


Contacts
Layout table for location contacts
Contact: Epp Goodwin 210-450-1000 ctrcreferral@uthscsa.edu

Locations
Layout table for location information
United States, Texas
University of Texas Health Science Center San Antonio at the Cancer Therapy and Research Center Recruiting
San Antonio, Texas, United States, 78229
Contact: Epp Goodwin       CTRCReferral@uthscsa.edu   
Principal Investigator: Andew Brenner, MD         
Sub-Investigator: Adolfo E. Diaz-Duque, MD         
Sponsors and Collaborators
The University of Texas Health Science Center at San Antonio
Investigators
Layout table for investigator information
Principal Investigator: Andrew Brenner UT Health San Antonio

Layout table for additonal information
Responsible Party: Andrew Brenner, Clinical Investigator, The University of Texas Health Science Center at San Antonio
ClinicalTrials.gov Identifier: NCT03032484     History of Changes
Other Study ID Numbers: CTMS# 16-0136
First Posted: January 26, 2017    Key Record Dates
Last Update Posted: October 26, 2018
Last Verified: October 2018
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No

Additional relevant MeSH terms:
Layout table for MeSH terms
Astrocytoma
Glioma
Neoplasms, Neuroepithelial
Neuroectodermal Tumors
Neoplasms, Germ Cell and Embryonal
Neoplasms by Histologic Type
Neoplasms
Neoplasms, Glandular and Epithelial
Neoplasms, Nerve Tissue
Bevacizumab
Antineoplastic Agents, Immunological
Antineoplastic Agents
Angiogenesis Inhibitors
Angiogenesis Modulating Agents
Growth Substances
Physiological Effects of Drugs
Growth Inhibitors